H3K27me3

Small Molecule Shows Early-Stage Promise for Repairing Myelin Sheath Damage

Retrieved on: 
木曜日, 5月 2, 2024
Nerve, Brain, Enzyme, University, Cell nucleus, Mouse, Tissue, H3K9me3, Organoid, Thought, H3K27ac, Doctor of Philosophy, Axon, Research, Remyelination, Disease, OLS, Cholesterol, Movement, Gene expression, Multiple sclerosis, Regeneration, Ageing, H3K27me3, Tetraplegia, Pharmaceutical industry

CINCINNATI, May 2, 2024 /PRNewswire/ -- When treated with a novel protein function inhibitor called ESI1, mice that mimic the symptoms of multiple sclerosis (MS) and lab-prepared human brain cells both demonstrated the ability to regenerate vital myelin coatings that protect healthy axon function.

Key Points: 
  • When the protective myelin gets damaged, be it by disease or the wear and tear of age, nerve signaling gets disrupted.
  • Pinning down the genetic changes and signals involved in the repair silencing process and finding a small molecule compound that can reverse the silencing was a complex undertaking.
  • In both aging mice and mice mimicking MS, the ESI1 treatment prompted myelin sheath production and improved lost neurological function.
  • When the organoids were exposed to ESI1, the treatment extended the myelin sheath of myelinating cells, the study reports.

ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

Retrieved on: 
月曜日, 1月 8, 2024
PRC2, CYP, Conference, Lung cancer, ESMO, Partnership, HER2, Breast, Half-life, Prostate cancer, SAN, H3K27me3, CNS, Monocyte, Investment, Webcast, Patient, PIPE, PLK4, TRIM37, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced initial data for its PRC2 inhibitor ORIC-944, operational highlights for 2023, and anticipated upcoming milestones.

Key Points: 
  • Presented initial data from the ongoing Phase 1b dose escalation trial for patients with EGFR or HER2 exon 20 mutated non-small cell lung cancer (NSCLC) at the ESMO Congress 2023.
  • Presented preclinical data for ORIC-114 at ESMO Congress 2023, demonstrating potent activity across atypical mutations in EGFR, thus expanding the potential patient population.
  • Presented preclinical data highlighting a comprehensive biomarker strategy for the ongoing Phase 1b trial in metastatic prostate cancer at the 2023 AACR Annual Meeting.
  • Presented initial data from Phase 1b trial of ORIC-533 in patients with relapsed/refractory multiple myeloma at the 2023 ASH Annual Meeting.

ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
火曜日, 4月 18, 2023
AACR, H3K27me3, PD, Neoplasm, Aurora kinase B, Breast, EED, Biomarker, Doctor of Philosophy, PRC2, PLK4, Plasma, Phase 1, Patient, SAN, Cancer, Mouse, TRIM37, Gene, ORIC, Pharmaceutical industry, Fused quartz, Vaccine

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented two preclinical poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented two preclinical poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
  • “Our presentations at AACR reflect the excellent preclinical scientific support of our development pipeline,” said Lori Friedman, PhD, chief scientific officer.
  • “Preclinical data provided insights into the comprehensive biomarker strategy for ORIC-944, our PRC2 inhibitor in Phase 1 as a monotherapy for metastatic prostate cancer.
  • Together these mechanistic data confirm the potential of highly selective PLK4 inhibition as a synthetic lethal therapy for TRIM37 amplified/elevated cancers.

Ascentage Pharma to Present Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022

Retrieved on: 
火曜日, 3月 8, 2022
MSD, Priority review, Apoptosis, Drug resistance, BTD, AACR, American Association for Cancer Research, Center for Drug Evaluation and Research, Infection, CDE, CHB, FTD, H3K27me3, Research, Therapy, FAK, Unity Biotechnology, Degenerative disease, Stock exchange, AstraZeneca, Mutation, MD Anderson Cancer Center, National Medical Products Administration, KRAS, Multimedia, NMPA, IAP, Cancer, Mesothelioma, Motherboard, EED, Dana–Farber Cancer Institute, Patient, Treatment, TKI, California Department of Alcohol and Drug Programs, American Association, TP53, 2021 Essex County Council election, Center, Autophagy, Hepatitis, GDP, Mayo Clinic, Biotechnology, CML, Association, ODD, The Pauly D Project, Pharmaceutical industry, Fine chemical, Communications satellite, Potash, EU, Pfizer

The AACR annual meeting is one of the world's largest and long-standing scientific gatherings in the field of cancer research.

Key Points: 
  • The AACR annual meeting is one of the world's largest and long-standing scientific gatherings in the field of cancer research.
  • This year's AACR annual meeting will be held in the city of New Orleans, United States, on April 8-13, 2022.
  • These six abstracts from Ascentage Pharma include:
    Time: 9:00 AM 12:30 PM CST, April 13, 2022
    BCL-2 mutation is a key mechanism driving the drug-resistance to BCL-2 inhibitors.
  • Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases.

Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data

Retrieved on: 
月曜日, 12月 6, 2021
Patient, Volunteering, Review, Safety, Half-life, HBG, PK, Fetal hemoglobin, Sickle cell disease, Fulcrum, KOL, HBF, Thalassemia, Pharmacokinetics, Doctor of Philosophy, Disease, BCL11A, MAD, Eye, Hematology, Nasdaq, Genetics, H3K27me3, GLOBE, Adult, SAD, RNA transfection, Mortality, Therapy, Hemoglobinopathy, MYB, Dietary supplement, Pharmaceutical industry, Vaccine

Data from the 20mg and 30mg dose cohorts demonstrated a mean 5.6-fold induction and a mean 6.2-fold induction in HBG mRNA, respectively, at day 14.

Key Points: 
  • Data from the 20mg and 30mg dose cohorts demonstrated a mean 5.6-fold induction and a mean 6.2-fold induction in HBG mRNA, respectively, at day 14.
  • These increases were higher than those observed in the previously reported 2, 6 and 10mg dose cohorts.
  • In preclinical studies of FTX-6058, increases in HBG mRNA have consistently translated to the same fold increases in HbF protein.
  • The data also showed higher-fold induction of HBG mRNA at the higher doses, with FTX-6058 achieving maximal rate of HBG mRNA induction in the 20mg and 30mg cohorts.

Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

Retrieved on: 
火曜日, 8月 10, 2021
IND, Birmingham, Patient, A Call for Unity, Sickle cell disease, Adult, Fetal hemoglobin, Kinetics, PRC2, Clinical trial, Half-life, Program, Monocyte, Nasdaq, Safety, SCD, HBG, Biology, HBF, Hemoglobinopathy, Investigational New Drug, RNA transfection, H3K27me3, PD, EED, Pharmacokinetics, GLOBE, Volunteering, University, SAD, Thalassemia, MAD, Lysine, Erythropoiesis, Therapy, Pharmaceutical industry, Vaccine

The increases in F-reticulocytes indicate that the HBG mRNA increases observed with FTX-6058 treatment are translating to HbF protein production.

Key Points: 
  • The increases in F-reticulocytes indicate that the HBG mRNA increases observed with FTX-6058 treatment are translating to HbF protein production.
  • These results with FTX-6058 are very encouraging, said Julie Kanter, MD, co-director, Lifespan Comprehensive Sickle Cell Center at the University of Alabama at Birmingham.
  • We look forward to moving this program forward into a trial in people living with sickle cell disease in the fourth quarter of 2021.
  • FTX-6058 Phase 1 Healthy Volunteer Trial to Assess Safety, Tolerability, and Pharmacokinetics
    The Phase 1 randomized, double-blind, placebo-controlled trial is designed to evaluate the safety, tolerability, and pharmacokinetics of FTX-6058 ( NCT04586985 ).